title: Studies on analogs of a peptide derived from alpha-fetoprotein having antigrowth properties.
abstract: A 34-amino acid portion of the third domain of alpha-fetoprotein possesses antigrowth and anticancer activities. Three analogs of this sequence were chemically synthesized, in which the two cysteines of the original sequence were replaced by alanines, glycines or serines. The original cysteine and alanine peptides formed trimers at 0.20 g/L in pH 7.4 phosphate buffer, and the glycine and serine peptides formed dimers. Trimer preparations were more potent in inhibiting estrogen-induced growth in the mouse uterine assays than the two dimeric oligomers. Of salient importance is that the alanine peptide retained its trimeric form in solution much longer than the cysteine peptide. Antigrowth assays were performed starting with stock solutions at a peptide concentration of 0.20 g/L, because at very high peptide concentration (8.0 g/L) the peptides aggregated extensively. All the peptides, although differing in biological activity, had almost identical secondary structures. Unlike alpha-fetoprotein, the three peptides have low amounts of alpha-helix. Trifluoroethanol has the ability to convert peptides into a helical conformation when they have a propensity for that structure. At trifluoroethanol concentrations of 20% and higher, the alanine and glycine peptides were changed into highly helical structures.
authors: Wadsworth Center, New York State Department of Health, Albany, NY 12201-0500, USA.
authors: L E
authors: LE
authors: Eisele
authors: F B
authors: FB
authors: Mesfin
authors: J A
authors: JA
authors: Bennett
authors: T T
authors: TT
authors: Andersen
authors: H I
authors: HI
authors: Jacobson
authors: D D
authors: DD
authors: Vakharia
authors: R
authors: R
authors: MacColl
authors: G J
authors: GJ
authors: Mizejewski
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives / Q000737:chemistry; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D002850:Chromatography, Gel; D003545:Cysteine / Q000031:analogs & derivatives / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D000939:Epitopes; D004967:Estrogens / Q000378:metabolism; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives / Q000737:chemistry; D006801:Humans; D006863:Hydrogen-Ion Concentration; D051379:Mice; D010455:Peptides / Q000737:chemistry* / Q000494:pharmacology*; D017433:Protein Structure, Secondary; D012694:Serine / Q000031:analogs & derivatives / Q000737:chemistry; D013997:Time Factors; D014599:Uterus / Q000187:drug effects; D000509:alpha-Fetoproteins / Q000737:chemistry* / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D000939:Epitopes; D004967:Estrogens; D010455:Peptides; D000509:alpha-Fetoproteins; D012694:Serine; D003545:Cysteine; D000409:Alanine; D005998:Glycine